Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Regeneron Pharmaceuticals (REGN)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$902.90-2.98%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
61.85 → 70.32 EPS · FY ending Dec 31, 2027 · 10 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 6, 2026 to Nov 5, 2026: (new ÷ prior − 1). Contributor count changed from 9 to 10; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for REGN yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Control GAAP effective tax rate within 12%-14% in FY26 | A supporting condition in Regeneron Pharmaceuticals's published investment case. The stated target is 12%-14%. | Under Pressure | Effective tax rate rises above 14% in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
REGN is a large pharmaceutical business with a multi-year thesis tied to developing new medicines and expanding established products. The thesis is intact, and the latest results strengthened the recent business signal, though confidence in the evidence is medium.
The valuation evidence describes REGN as cheap versus peers, with a small expectations gap and low signs of fragility. That suggests the market is not pricing in especially demanding expectations, but the evidence does not establish that the shares are cheap in absolute terms.
Near term, recent financial performance is strong: revenue increased between the cited quarters, and the latest update reported higher sales for Dupixent, EYLEA HD, and Libtayo. Management has kept pipeline development and medicine growth as priorities, while higher research spending supports that effort; manufacturing investment remains an area to watch despite production returning to normal at Limerick.
The multi-year thesis depends on continued pipeline progress and growth in key medicines, alongside reliable manufacturing execution. Near term, a guidance cut would be a meaningful setback, while weakening employment data could add pressure through recession concerns; continued strong results from healthcare peers would support the sector backdrop.
For the next one to three years, the business setup remains constructive, but the thesis depends on sustained product growth, pipeline progress, and steady execution. Near-term guidance and manufacturing remain important watch points. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in Regeneron Pharmaceuticals's published investment case. The stated target is 77%-80%. |
| Under Pressure |
| Gross margin falls below 77% in FY26 |
Gross margin: 88.79% FY2026-Q3; GAAP. Published target: 77%-80%. Annual target cannot be compared with a quarterly or TTM observation. Oct 30, 202688.787677 percent · calculatedLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Advance pipeline with new product launches and FDA fast-track designations | FDA fast-track programs speed product approvals. | Intact | Pipeline progress stalls or FDA fast-track designations are lost | Pipeline advancing with ~50 candidates and new data Regeneron reported Q3 beat, expanded Sanofi partnership, and positive oncology data for ubamatamab, supporting pipeline momentum. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Regeneron revenue grows at least 11.6% in FY26 | Regeneron grows sales about 12% a year with new drug launches. | Intact | YoY revenue growth falls below 7% in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$47.46 → $70.32 · observed estimates
$17.65B → $20.10B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $47.46 | $17,646,861,710 | 9 / 23 |
| 2026-07-25 | $47.40 | $17,607,941,730 | 9 / 22 |
| 2026-07-26 | $53.53 | $17,578,938,110 | 9 / 17 |
| 2026-07-27 | $47.40 | $17,607,941,730 | 9 / 22 |
| 2026-07-28 | $47.40 | $17,607,941,730 | 9 / 22 |
| 2026-07-29 | $53.53 | $17,578,939,835 | 9 / 17 |
| 2026-07-30 | $47.36 | $17,609,494,050 | 9 / 22 |
| 2026-07-31 | $48.53 | $17,846,008,160 | 10 / 24 |
| 2026-08-01 | $58.49 | $18,219,832,996 | 9 / 18 |
| 2026-08-02 | $50.21 | $18,310,875,200 | 10 / 25 |
| 2026-08-03 | $58.64 | $18,326,999,663 | 10 / 19 |
| 2026-08-04 | $58.64 | $18,326,999,663 | 10 / 19 |
| 2026-08-05 | $50.21 | $18,310,875,200 | 10 / 25 |
| 2026-08-06 | $58.64 | $18,326,999,663 | 10 / 19 |
| 2026-08-08 | $50.40 | $18,340,113,910 | 10 / 25 |
| 2026-08-09 | $50.40 | $18,340,113,910 | 10 / 25 |
| 2026-08-10 | $58.64 | $18,326,999,663 | 10 / 19 |
| 2026-08-12 | $58.64 | $18,326,999,663 | 10 / 19 |
| 2026-08-13 | $58.64 | $18,326,999,663 | 10 / 19 |
| 2026-08-14 | $58.64 | $18,326,999,663 | 10 / 19 |
| 2026-08-15 | $58.64 | $18,326,999,663 | 10 / 19 |
| 2026-08-16 | $58.64 | $18,326,999,663 | 10 / 19 |
| 2026-08-17 | $58.64 | $18,326,999,663 | 10 / 19 |
| 2026-08-18 | $58.64 | $18,326,999,663 | 10 / 19 |
| 2026-08-19 | $58.64 | $18,326,999,663 | 10 / 19 |
| 2026-08-20 | $60.88 | $18,554,459,951 | 10 / 19 |
| 2026-08-21 | $60.88 | $18,554,451,068 | 10 / 19 |
| 2026-08-22 | $60.88 | $18,554,451,068 | 10 / 19 |
| 2026-08-23 | $60.88 | $18,554,451,068 | 10 / 19 |
| 2026-08-24 | $60.88 | $18,554,451,068 | 10 / 19 |
| 2026-08-25 | $60.88 | $18,554,451,068 | 10 / 19 |
| 2026-08-26 | $60.88 | $18,554,451,068 | 10 / 19 |
| 2026-08-27 | $60.88 | $18,554,451,068 | 10 / 19 |
| 2026-08-28 | $60.88 | $18,554,451,068 | 10 / 19 |
| 2026-08-29 | $60.88 | $18,554,451,068 | 10 / 19 |
| 2026-08-30 | $60.88 | $18,554,451,068 | 10 / 19 |
| 2026-08-31 | $60.88 | $18,554,451,068 | 10 / 19 |
| 2026-09-01 | $60.88 | $18,554,451,068 | 10 / 19 |
| 2026-09-02 | $60.88 | $18,554,451,068 | 10 / 19 |
| 2026-09-03 | $60.88 | $18,554,298,003 | 10 / 19 |
| 2026-09-04 | $60.88 | $18,554,298,003 | 10 / 19 |
| 2026-09-05 | $60.78 | $18,584,275,380 | 10 / 19 |
| 2026-09-06 | $60.78 | $18,584,275,380 | 10 / 19 |
| 2026-09-07 | $60.78 | $18,584,275,380 | 10 / 19 |
| 2026-09-08 | $60.78 | $18,584,275,380 | 10 / 19 |
| 2026-09-09 | $60.95 | $18,590,569,062 | 10 / 18 |
| 2026-09-10 | $61.16 | $18,634,668,411 | 10 / 18 |
| 2026-09-11 | $61.24 | $18,602,653,097 | 10 / 18 |
| 2026-09-12 | $61.24 | $18,602,653,097 | 10 / 18 |
| 2026-09-13 | $61.24 | $18,602,653,097 | 10 / 18 |
| 2026-09-14 | $61.24 | $18,602,653,097 | 10 / 18 |
| 2026-09-15 | $61.24 | $18,602,653,097 | 10 / 18 |
| 2026-09-16 | $61.24 | $18,602,653,097 | 10 / 18 |
| 2026-09-17 | $61.24 | $18,602,658,515 | 10 / 18 |
| 2026-09-18 | $61.24 | $18,602,658,515 | 10 / 18 |
| 2026-09-19 | $61.24 | $18,602,658,515 | 10 / 18 |
| 2026-09-20 | $61.24 | $18,602,658,515 | 10 / 18 |
| 2026-09-21 | $61.24 | $18,602,658,515 | 10 / 18 |
| 2026-09-22 | $61.24 | $18,602,658,515 | 10 / 18 |
| 2026-09-23 | $61.24 | $18,602,658,515 | 10 / 18 |
| 2026-09-24 | $61.24 | $18,602,658,515 | 10 / 18 |
| 2026-09-25 | $61.24 | $18,602,658,516 | 9 / 18 |
| 2026-09-26 | $61.24 | $18,602,651,946 | 9 / 17 |
| 2026-09-27 | $61.24 | $18,602,651,946 | 9 / 17 |
| 2026-09-28 | $61.24 | $18,602,651,946 | 9 / 17 |
| 2026-09-29 | $61.24 | $18,602,646,529 | 9 / 17 |
| 2026-09-30 | $61.24 | $18,602,646,529 | 9 / 17 |
| 2026-10-01 | $61.24 | $18,602,646,529 | 9 / 17 |
| 2026-10-02 | $61.24 | $18,602,646,529 | 9 / 17 |
| 2026-10-03 | $61.86 | $18,602,494,434 | 9 / 18 |
| 2026-10-04 | $61.86 | $18,602,494,434 | 9 / 18 |
| 2026-10-05 | $61.86 | $18,602,494,434 | 9 / 18 |
| 2026-10-06 | $61.85 | $18,597,481,100 | 9 / 18 |
| 2026-10-07 | $62.13 | $18,643,219,686 | 9 / 17 |
| 2026-10-08 | $62.13 | $18,643,219,686 | 9 / 17 |
| 2026-10-09 | $62.21 | $18,681,132,730 | 9 / 17 |
| 2026-10-10 | $62.21 | $18,681,132,730 | 9 / 17 |
| 2026-10-11 | $62.21 | $18,681,111,882 | 9 / 17 |
| 2026-10-12 | $62.21 | $18,681,111,882 | 9 / 17 |
| 2026-10-13 | $62.53 | $18,759,995,523 | 9 / 17 |
| 2026-10-14 | $62.54 | $18,759,995,523 | 9 / 17 |
| 2026-10-15 | $62.54 | $18,759,995,523 | 9 / 17 |
| 2026-10-16 | $62.56 | $18,741,104,284 | 9 / 17 |
| 2026-10-17 | $62.56 | $18,741,104,284 | 9 / 17 |
| 2026-10-18 | $62.56 | $18,741,104,283 | 9 / 17 |
| 2026-10-19 | $62.56 | $18,741,104,283 | 9 / 17 |
| 2026-10-20 | $62.57 | $18,734,434,466 | 9 / 17 |
| 2026-10-21 | $62.57 | $18,734,434,466 | 9 / 17 |
| 2026-10-22 | $62.63 | $18,741,724,862 | 9 / 17 |
| 2026-10-23 | $63.43 | $18,737,259,646 | 9 / 17 |
| 2026-10-24 | $63.43 | $18,737,259,646 | 9 / 17 |
| 2026-10-25 | $63.43 | $18,737,259,646 | 9 / 17 |
| 2026-10-26 | $63.43 | $18,737,259,646 | 9 / 17 |
| 2026-10-27 | $63.43 | $18,737,259,646 | 9 / 17 |
| 2026-10-28 | $63.43 | $18,737,259,646 | 10 / 17 |
| 2026-10-29 | $63.55 | $18,737,259,646 | 10 / 17 |
| 2026-10-30 | $63.55 | $18,737,259,646 | 10 / 17 |
| 2026-10-31 | $67.95 | $19,677,634,850 | 10 / 17 |
| 2026-11-01 | $67.95 | $19,677,634,850 | 9 / 17 |
| 2026-11-02 | $69.23 | $19,826,051,517 | 10 / 18 |
| 2026-11-03 | $70.21 | $20,045,846,723 | 10 / 18 |
| 2026-11-04 | $70.32 | $20,095,531,901 | 10 / 18 |
| 2026-11-05 | $70.32 | $20,095,531,901 | 10 / 18 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 19 Buy / Strong Buy · 9 Hold · 1 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 21 recorded
9 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.